<DOC>
	<DOCNO>NCT00317395</DOCNO>
	<brief_summary>Primary objective : To demonstrate clinical efficacy otamixaban ( dose effect via 5 intravenous [ IV ] regimen ) patient moderate-to-high-risk non-ST elevation acute coronary syndrome ( ACS ) plan early invasive strategy . Secondary objective : To evaluate safety ass pharmacokinetics ( PK ) pharmacodynamics ( PD ) .</brief_summary>
	<brief_title>Study Otamixaban Versus Unfractionated Heparin ( UFH ) Eptifibatide Non-ST Elevation Acute Coronary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Otamixaban</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Eptifibatide</mesh_term>
	<criteria>Ischemic discomfort rest â‰¥ 10 minute within 24 hour randomization Electrocardiogram ( ECG ) criterion nonST elevation ACS cardiac enzyme elevation ( &gt; upper limit normal [ ULN ] ) No ST elevation Myocardial Infarction ( STEMI ) Planned coronary angiography follow indicated Percutaneous Coronary Intervention ( PCI ) Day 1 Day 3 Inability undergo coronary angiography PCI Day 3 Prior PCI within 30 day Acute STEMI Cardiogenic shock Anticoagulant treatment &gt; 24 hour prior randomization Prior treatment fondaparinux since ACS onset Requirement oral anticoagulant ( OAC ) prior Day 30 Creatinine clearance &lt; 30 ml/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Non ST elevation Acute Coronary Syndrome</keyword>
	<keyword>Early invasive strategy</keyword>
	<keyword>Percutaneous Coronary Intervention</keyword>
</DOC>